Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ANAB stock hub

AnaptysBio, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ANABis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ANAB

In the news

Latest news · ANAB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E78

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-24.5

P25 -105.6P50 -46.5P75 -3.1

ROIC7.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ANAB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

223

Groups with data

Currency

USD

Showing 223 of 223 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001370053
Company name	AnaptysBio, Inc.
Country	United States
Country code	US
Cusip	032724106
Employees	104
Employees Change	-32%
Employees Change Percent	-23.53
Enterprise value	$2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2017-01-26
Isin	US0327241065
Last refreshed	2026-05-10
Market cap	$2B
Market cap category	Small-Cap
Price	$69.3
Price currency	USD
Rev Per Employee	2,255,798.08x
Sector	Healthcare
Sic	2834
Symbol	ANAB
Website	https://www.anaptysbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.66%
EV Sales Forward	15.63x
EV/EBIT	41.18x
EV/EBITDA	40.7x
EV/FCF	100.57x
EV/Sales	8.41x
FCF yield	0.98%
Forward P/E	77.96x
P/B ratio	52.21x
P/S ratio	8.5x
PS Forward	15.79x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	20.42%
EBITDA Margin	20.65%
FCF margin	8.36%
Gross margin	42.04%
Gross Profit	$98.6M
Gross Profit Growth Q	15,680.53%
Net Income	$-13.2M
Net Income Growth Quarters	6%
Net Income Growth Years	2%
Pretax Margin	-5.57%
Profit Margin	-5.64%
Profit Per Employee	$-127,231
ROA	7.06
Roa5y	-8.99
ROCE	14.7
ROE	-24.49
Roe5y	-71.52
ROIC	7.79

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	428.88%
Cagr3y	68.05%
Cagr5y	31.79%
EPS Growth Quarters	6
EPS Growth Years	2
Revenue Growth	157.02x
Revenue Growth Q	151.08x
Revenue Growth Quarters	13x
Revenue Growth Years	3x
Revenue Growth3 Y	183.58x
Revenue Growth5 Y	25.62x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.55
Assets	$364.4M
Cash	$311.6M
Current Assets	$350.3M
Current Liabilities	$38.6M
Debt	$290.6M
Debt EBITDA	$5.71
Debt Equity	$7.81
Debt FCF	$14.82
Equity	$37.2M
Interest Coverage	0.6
Liabilities	$327.2M
Long Term Assets	$14.1M
Long Term Liabilities	$288.6M
Net Cash	$21M
Net Cash By Market Cap	$1.05
Net Cash Growth	31.98%
Net Debt EBITDA	$-0.43
Net Debt Equity	$-0.56
Net Debt FCF	$-1.07
Tangible Book Value	$37.2M
Tangible Book Value Per Share	$1.33
WACC	8.8

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.07
Net Working Capital	$2.1M
Quick ratio	8.94
Working Capital	$311.6M
Working Capital Turnover	$0.67

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.33%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	428.28%
200-day SMA	42.79
3Y total return	374.73%
50-day SMA	62.41
50-day SMA vs 200-day SMA	50over200
5Y total return	297.42%
All Time High	134
All Time High Change	-48.28%
All Time High Date	2018-02-20
All Time Low	10
All Time Low Change	593%
All Time Low Date	2019-11-08
ATR	5.35
Beta	0.48
Beta1y	0.24
Beta2y	0.83
Ch YTD	42.95
High	70.07
High52	73.3
High52 Date	2026-04-13
High52ch	-5.46%
Low	66.01
Low52	17.11
Low52 Date	2025-09-16
Low52ch	305.12%
Ma50ch	11.05%
Premarket Change Percent	-0.57
Premarket Price	$66.58
Premarket Volume	259
Price vs 200-day SMA	61.95%
RSI	57.98
RSI Monthly	78.2
RSI Weekly	66.63
Sharpe ratio	2.66x
Sortino ratio	5.02
Total Return	-1.33%
Tr YTD	114.5
Tr1m	67.34%
Tr1w	3.81%
Tr3m	109.06%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	7
Analyst Price Target Top	$81.29
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.66
Earnings Revenue Estimate	18,871,200x
Earnings Revenue Estimate Growth	-32.05x
Operating Income	$47.9M
Operating margin	20.42
Price target	$71.5
Price Target Change	$3.18
Price Target Change Top	$17.3

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	17,263,009%
Float Percent	60.05%
Shares Insiders	2.93%
Shares Institutions	65.62%
Shares Out	28,748,255
Shares Qo Q	8.01%
Shares Yo Y	1.33%
Short Float	23.79%
Short Ratio	6.57
Short Shares	14.28

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-16.5M
Average Volume	729,632.7x
Bv Per Share	1.33
CAPEX	$-87,000
Ch1m	11.54
Ch1w	3.81
Ch1y	252.1
Ch3m	39.35
Ch3y	216.4
Ch5y	164.9
Ch6m	74.78
Change	3.49%
Change From Open	3.56
Close	66.96
Days Gap	-0.06
Depreciation Amortization	559,000
Dollar Volume	32,061,090.6
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$47.9M
EBITDA	$48.5M
EPS	$-0.46
F Score	6
FCF	$19.6M
FCF EV Yield	0.99x
FCF Per Share	$0.68
Financing CF	-132,613,000
Fiscal Year End	December
Founded	2,005
Income Tax	$164,000
Investing CF	228,032,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-03
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-03
Ma150	49.56
Ma150ch	39.82%
Ma20	63.9
Ma20ch	8.45%
Net CF	115,116,000
Next Earnings Date	2026-05-22
Open	66.92
Optionable	Yes
P FCF Ratio	101.6
P OCF Ratio	101.2
Position In Range	81.03
Post Close	69.3
Postmarket Change Percent	0.04
Postmarket Price	$69.33
Ppne	13,889,000
Pre Close	66.96
Price Date	2026-05-08
Price EBITDA	$41.13
Ptbv Ratio	53.56
Relative Volume	0.63x
Revenue	234,603,000x
SBC By Revenue	15.38x
Share Based Comp	36,072,000
Tax By Revenue	0.07x
Tr6m	162.21%
Us State	California
Volume	462,642
Z Score	0.46

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ANAB pay a dividend?

Capital-return profile for this ticker.

Performance

ANAB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ANAB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+65.6%

Float: +60.0% of shares outstanding

Insider ownership

+2.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ANAB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

58.0

Neutral momentum band

Price vs 200-day MA

+61.9%

50/200-day relationship not available

Beta (5Y)

0.48

Less volatile than the market

Sharpe ratio

2.65

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ANAB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ANAB stock rating?

AnaptysBio, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ANAB analysis?

The full report lives at /stocks/ANAB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ANAB?

The latest report frames ANAB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ANAB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.